Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses Polymorphism Patent from Vanderbilt

NEW YORK, Jan. 26 (GenomeWeb News) - Genaissance Pharmaceuticals has exclusively licensed commercial rights to a patent held by Vanderbilt University that it said would expand its ability to provide genetic tests for variants of cardiac ion-channel proteins involved in drug-induced cardiac arrhythmias.


Genaissance gained rights to US Patent No. 6,458,542, which covers the screening of patients for susceptibility of drug-induced cardiac arrhythmias by testing for the presence of a common polymorphism in KCNE1, a cardiac ion channel gene. The patent adds to Genaissance's estate of more than 50 issued and pending patents covering five cardiac ion-channel genes associated with Long QT Syndrome.


New Haven, Conn.-based Genaissance developed the Familion Test for cardiac channelopathies, including Long QT Syndrome and Brugada Syndrome.


Terms of the license were not disclosed.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.